Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 20, Issue 44, Pages 16630-16638Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v20.i44.16630
Keywords
Ablation therapy; Biotherapy; Hepatocellular carcinoma; Hormonal therapy; Percutaneous ethanol injection; Percutaneous microwave coagulation therapy; Radiofrequency ablation; Radiotherapy; Transcatheter arterial chemoembolization; Chemotherapy
Categories
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death worldwide. There have been great improvements in the diagnosis and treatment of HCC in recent years, but the problems, including difficult diagnosis at early stage, quick progression, and poor prognosis remain unsolved. Surgical resection is the mainstay of the treatment for HCC. However, 70%-80% of HCC patients are diagnosed at an advanced stage when most are ineligible for potentially curative therapies such as surgical resection and liver transplantation. In recent years, non-surgical management for unrespectable HCC, such as percutaneous ethanol injection, percutaneous microwave coagulation therapy, percutaneous radiofrequency ablation, transcatheter arterial chemoembolization, radiotherapy, chemotherapy, bio-therapy, and hormonal therapy have been developed. These therapeutic options, either alone or in combination, have been shown to control tumor growth, prolong survival time, and improve quality of life to some extent. This review covers the current status and progress of non-surgical management for HCC. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available